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1 
METHOD OF IDENTIFYING AND 
TREATING INVASIVE CARCINOMAS 
This invention relates to prostasin and its use in the 
diagnosis and treatment of prostate and breast cancers, and 
is a Continuation-In-Part (CIP) of application Ser. No. 
09/755,811 filed Jan. 5, 2001 now U.S. Pat. No. 6,569,684 
and claims the priority to U.S. Provisional application Ser. 
No. 60/174,801 filed Jan. 6, 2000 and was supported in part 
by Department of Defense Prostate Cancer Research Grant 
DAMD17-98-l-8590, and in part by grants to principal 
investigator K. X. CHAI from the Florida Hospital Gala 
Endowed Program for Oncologic Research. 
BACKGROUND AND PRIOR ART 
For men in the U.S. prostate cancer is the most commonly 
diagnosed cancer, and the second leading cause of cancer-
related death (Greenlee RT, Murray F. Bolden S, Wingo P 
A Cancer statistics, 1999. Ca: a Cancer Journal for Clini-
cians 2000;50:7-33). Prostate cancers originate as localized 
lesions; some of these localized lesions will progress to 
become invasive, migratory and metastatic. Our current 
understanding of the mechanisms of the prostate cancer 
invasion process, however, is poor. Our ability to predict the 
acquisition of invasive potentials by a prostate cancer is 
limited. 
The mechanisms leading to the development of a prostate 
cancer are complex. Currently, it is believed to be the result 
of multiple transformation steps from normal prostate glan-
dular cells (Carter H B. Piantadosi S. Isaacs J T. Clinical 
evidence for and implications of the multistep development 
of prostate cancer. Journal of Urology. 143(4):742-6, 1990). 
The initial steps result in what are described as prostatic 
interepithelial neoplastic (PIN) lesions (Isaacs J T. Molecu-
lar markers for prostate cancer metastasis. Developing diag-
nostic methods for predicting the aggressiveness of prostate 
cancer. [Review] [92 refs] American Journal of Pathology. 
150(5):1511-21, 1997). These PIN lesions may then typi-
cally have three different fates based on an assessment of 
their impact to the patient. The PIN lesions can remain as 
such, not producing histologically detectable prostate 
cancer, or further transform into histologically detectable 
prostate cancer. Most of the histologically detectable pros-
tate cancers will be asymptomatic in the patient and remain 
non-manifest clinically as many are discovered post-mortem 
(Carter H Coffey D. Prostate Cancer: the magnitude of the 
problem in the United States. In a Multidisciplinary Analysis 
of Controversies in the Management of Prostate Cancer. 
(Eds. Coffey D. Resnick M. Door R. et al.), ppl-9, Plenum 
Press, 1988; Carter H B Piantadosi S. Issacs J T. Clinical 
evidence for implications of the multistep development of 
prostate cancer. Journal of Urology. 143(4):742-6, 1990; 
Scardino P T. Weaver R. Hudson M A Early detection of 
prostate cancer. [Review] [102 refs] Human Pathology. 
23(3):211-22, 1999). Prostate cancers are diagnosed clini-
cally by an estimate of size and location using the TNM 
staging system (Denis L J. Staging and prognosis of prostate 
cancer. European Urology. 24 Suppl 2:13-8, 1993), and by 
pathological staging based on an examination of the histol-
ogy of the removed prostate via either biopsy or prostatec-
tomy using a system by D. F. Gleason, (Gleason D F. 
Classification of prostatic carcinomas. Cancer Chemo-
therapy Reports-Part 1. 50(3):125-8, 1966). About 50% of 
prostate cancer cases receiving treatment are diagnosed 
clinically as advanced, or, non-organ-confined (Scardino P 
T. Weaver R. Hudson M A Early detection of prostate 
cancer. [Review] [102 refs] Human Pathology. 23(3): 
2 
211-22, 1992), for which no effective treatment exists 
(Yagoda A Petrylak D. Cytotoxic chemotherapy for 
advanced hormone-resistant prostate cancer. [Review] [ 63 
refs] Cancer. 71(3 Suppl): 1098-109, 1993 and Petrylak, 
5 1993). Of the remaining 50% cases, 1/3 (-50,000) are diag-
nosed as organ-confined but micrometastasis may be 
present. The final group of patients (-100,000) have truly 
organ-confined prostate cancer and can be cured by radical 
prostatectomy (Sgrignoli AR Walsh P C. Steinberg G D. 
10 Steiner M S. Epstein J I. Prognostic factors in men with 
stage D 1 prostate cancer: identification of patients less 
likely to have prolonged survival after radical prostatectomy 
[see comments]. Journal of Urology. 152(4):1077-81, 1994; 
Zincke H. Oesterling J E. Blute ML. Bergstralh E J. Myers 
15 R P. Barrett D M. long term (15 years) results after radical 
prostatectomy for clinically localized (stageT2c or lower) 
prostate cancer [see comments]. Journal of Urology.152(5 Pt 
2): 1850--7, 1994) or left untreated (watchful waiting) with-
out the risk of life-threatening or life-altering. For the 
20 patients with non-organ-confined prostate cancers 
(discovered via either biopsy or surgery), undergoing sys-
temic treatment early is essential to the management of their 
cancer (Yagoda A Petrylak D. Cytotixic chemotherapy for 
1098-109, 1993). Consequently, it will be ideal, both medi-
25 cally and economically, if one could precisely predict upon 
early pathological examination of the tumor, which group of 
patients will have truly organ-confined disease versus which 
group will have invasive prostate cancer. 
Clinical staging of prostate cancer generally depends on 
30 the results of three tests that are performed in the following 
order: a PSA (prostate-specific antigen) blood test as a 
screening method; DRE (digital rectal examination) for an 
initial indication of palpable disease; and, a biopsy to obtain 
samples for histological examination. Prostate cancers, 
35 removed either via biopsy or surgery, are graded histologi-
cally by the system of Gleason. (Gleason D F. Classification 
of prostatic carcinomas. Cancer Chemotherapy Reports-
Partl. 50(3):125-8, 1966), which is an evaluation of how 
aggressive and how poorly-differentiated the prostate can-
40 cers are. The aggressiveness of prostate tumors: of low 
Gleason scores ( <5) is limited; of high Gleason scores 
(8-10) are highly aggressive; but, for the intermediate 
Gleason-score (5-7) prostate cancers (76% of prostate 
tumors), the accuracy of predicting their aggressiveness is 
45 poor (Gleason D F. Mellinger GT. Prediction of prognosis 
for prostatic adenocarcinoma by combined histological 
grading and clinical staging. Journal of Urology. 111(1): 
58-64, 1974). Thus, the ability to accurately determine the 
aggressiveness of these intermediate Gleason-score prostate 
50 tumors has remained as a practical challenge to, and a 
primary goal for, prostate cancer research (Isaacs J T. 
Molecular markers for prostate cancer metastasis. Develop-
ing diagnostic methods for predicting the aggressiveness of 
prostate cancer. [Review] [92 refs] American Journal of 
55 Pathology. 150(5):1511-21, 1997). Especially with regard to 
the number of patients (150,000) facing a decision of 
whether to undergo systemic treatment, the most urgent 
demand in prostate cancer care is the development of 
methods to enhance our ability to accurately predict the 
60 aggressiveness of the tumors with Gleason scores of 5-7. 
It is now commonly believed that cancers occur via 
multiple transformation steps by accumulating mutations in 
three classes of genes: proto-oncogenes (Park M. Onco-
genes. In The Genetic Basis of Human Cancer (Eds. Vogel-
65 stein Band Kinzler KW), pp205-28, McGraw-Hill Health 
Professions Divisions, 1998); tumor-suppressor genes 
(Knuutila S. Aalto Y. Bjorkqvist AM. EL-Rifai W. Hemmer 
US 6,864,093 Bl 
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S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S. Larramendy 
ML. Lushnikova T. Manni 0. Pere H. Tapper J. Tarkkanen 
4 
patients with prostate cancer. Cancer Research. 54(14): 
3929-33, 1994); ~ic integrin (Formaro M. Tallini G. Bofe-
tiado CJ. Bosari S. Languino LR. Down-regulation of ~lC 
integrin, an inhibitor of cell proliferation, in prostate carci-
M. Varis A Wasenius V M. Wolf M. Zhu Y. DNA copy 
number losses in human neoplasms. [Review] [197 refs] 
American Journal of Pathology. 155(3):683-94, 1999); and, 
DNA repair genes (Knuutila S. Aslto Y. Bjorkqvit A M. 
EL-Rifai W. Hemmer S. Huhta T. Kettunen E. Kiuru-
Kuhlefelt S. Larramedy ML. Lushnikova T. Manni 0. Pere 
5 noma. American Journal of Pathology. 149(3):765-73,1996 
Formaro M. Manzotti M. Tallini G. Stear A E. Bosari S. 
Ruoslahti E. Languino LR. ~lC integrin in epithelial cells 
correlates with a nonproliferative phenotype: forced expres-
sion of ~lC inhibits prostate epithelial cell proliferation. 
10 American Journal of Pathology. 153(4):1079-87, 1998; p27 
(kipl) (Tsihlias J. Kapusta LR. DeBoer G. Morava-Protzner 
I. Zbieranowski I. Bhattacharya N. Catzavelos G C. Klotz L 
H. Slingerland JM. Loss of cyclin-dependent kinase inhibi-
tor p27Kipl is a novel prognostic factor in localized human 
H. Tapper J. Tarkkanen M. Varis A Wasenius V M. Wolf M. 
Zhu Y. DNA copy number losses in human neoplasms. 
[Review] [197 refs] American Journal of Pathology. 155(3): 
683-94, 1999). The histological prostate cancers for which 
the prediction of clinical aggressiveness is difficult (those 
with the intermediate Gleason scores 5-7) probably have not 
gone through the necessary "multi-step" transformation to 
acquire the potentials to behave aggressively (as would the 
high-grade cancers). This notion was supported by studies 
comparing the course of prostate cancer development among 
men in Japan and in the U.S., and Japanese men who 
migrated to the U.S. (Carter H B. Piantadosi S. Isaacs J T. 20 
Clinical evidence for and implications of the multistep 
development of prostate cancer. Journal of Urology, 1990; 
Haenszel W. Kurihara M. Studies of Japanese Migrants. 1. 
Mortality form cancer and other diseases among Japanese in 
the United States. Journal of the National Cancer Institute.40 25 
(1):43-68, 1968; Akazaki K. Stemmerman G N. Comparar-
tive study of latent carcinoma of the prostate among Japa-
nese in Japan and Hawaii. Journal of the National Cancer 
Institute. 50(5):1137-44, 1973; Dunn J E. Cancer epidemi-
ology in populations of the United States-with emphasis on 30 
Hawaii and California-and Japan. Cancer Research. 35(11 
Pt.2):3240-5, 1975). The findings were that first- and 
second-generation Japanese men who migrated to the U.S. 
have a higher prostate cancer incident rate than native 
Japanese men. The emigrant Japanese men's prostate cancer 35 
incident rate is similar to that of men in the U.S. Investi-
gating the changes of expression in these three classes of 
cancer-relevant genes during the course of prostate cancer 
development will lead to a better understanding of the 
processes by which prostate cancers acquire their aggressive 40 
potentials. The discovery of molecules whose changes can 
15 prostate adenocarcinoma. Cancer Research. 58(3):542-8, 
1998); and CD44 (Lou W. Krill D. Dhir R. Becich M J. Dong 
J T. Frierson H F Jr. Isaacs W B. Isaacs J T. Gao A C. 
Methylation of the CD44 metastasis suppressor gene in 
human prostate cancer. Cancer Research. 59(10):2329-31, 
1999). By using the method of immunohistochemistry, these 
genes were found to be down-regulated in prostate cancer. 
KAI's down regulation is a potential predictor of metastasis 
(Dong, et al., 1996: Ueda et al., 1996). While 
E-cadherin'cadherin's down regulation is strongly corre-
lated to higher Gleason grades. Functional studies of these 
genes have given clues to their role in prostate cancer or 
normal prostate biology. (Debruyne F M. Isaacs W B. 
Expression of the cellular adhesion molecule E-cadherin is 
reduced or absent in high-grade prostate cancer. Cancer 
Research. 52(18):5104-9, 1992; Umbas R. Isaacs W B. 
Bringuier P P. Schaafsma H E. Karthaus H F. Oosterhof G 
0. Debruyne F M. Schalken J A Decreased E-cadherin 
expression is associated with poor prognosis in patients with 
prostate cancer. Cancer Research. 54(14):3929-33, 1994; 
metastasis suppressor gene during the progression of human 
prostatic cancer infrequently involves gene mutation or 
allelic loss. Cancer Research. 56(19):4387-90; 1996 Ueda T. 
Ichikawa T. Tamaru J. Mikata A Akakura K. Akimoto S. 
Imai T. Yoshie 0. Shiraishi T. Yatani R. Ito H. Shimazaki J. 
Expression of the KAil protein in benign prostatic hyper-
plasia and prostate cancer. American Journal of Pathology. 
149(5): 1435-40, 1996) while E-cadherin's down-regulation 
is strongly correlated to higher Gleason grades (Umbas R. 
Schalken J A Aalders T W. Carter B S. Karthaus H F. 
be correlated to the staging of prostate cancer will provide 
new tools to improve our ability to better predict the 
aggressive behaviors of prostate cancer. This approach is 
now commonly referred to as "molecular staging". 45 Schaafsma H E. Debruyne F M. Isaacs W B. Expression of 
the cellular adhesion molecule E-cadherin is reduced or Down-regulated genes such as tumor suppressors, inva-
sion suppressors or metastasis suppressors may be used as 
prostate cancer markers. Examples of these genes that can 
potentially serve as prostate cancer markers for "molecular 
staging" are: KAii (Dong J T. Suzuki H. Pin S S. Bova GS., 50 
Schalken JA, Issacs W B, Barrett JC. Issace I T. Down-
regulation of the KAI I metastasis suppressor gene during 
the progression of human prostatic cancer infrequently 
involves gene mutation or allelic loss. Cancer Research. 
56(19): 4387-90, 1996); (Ueda T, Ichikawa T., Tamaru j, 55 
Mikata A, Akakura K, Akimoto S, Imai T. Yoshie 0. 
Shiraishi T. Yatani R. Ito H. Shimazaki J., Expression fof the 
KAH protein in benign prostatic hyperplasia and prostate 
cancer. American Journal of Pathology 149(5): 1435-40, 
1996); E-cadherin (Umbas R. Isaacs WB BringuierP P. 60 
Schaafsma HE. Karthaus HF. Oosterhof G 0. Debruyne F 
M. Schalken J A Decreased E-Cadherin expression is 
associated with poor prognosis is patients with prostate 
cancer. Cancer Research. 52(18):5104-9, 1992, Umbas R. 
Isaacs W B. Bringuier P P. Schaafsma H E. Karthaus H F. 65 
Oosterhof G 0. Debruyne F M. Schalken J A Decreased 
E-cadherin expression is associated with poor prognosis in 
absent in high-grade prostate cancer. Cancer Research. 
52(18):5104-9,1992; Umbas R. Isaacs W B. Bringuier P P. 
Schaafsma HE. Karthaus HF. Oosterhof G 0. Debruyne F 
M. Schalken J A Decreased E-cadherin expression is asso-
ciated with poor prognosis in patients with prostate cancer. 
Cancer Research. 54(14):3929-33, 1994) Functional studies 
of these genes have given clues to their role in prostate 
cancer or normal prostate biology. Human KAI suppress 
metastasis of rat prostate cancer cells upon gene transfer 
(Dong J T. Lamb PW. Rinker-Schaeffer CW. Vukanovic J. 
Ichikawa T. Isaacs J T. Barrett J C. KAil, a metastasis 
suppressor gene for prostate cancer on human chromosome 
llpll.2 [see comments]. Science. 268(5212):884-6,1995). 
~ic and p27(kipl) are involved in signaling pathway that 
inhibits cell proliferation (Formaro M. Tallini G. Zheng D Q. 
Flanagan W M. Manzotti M. Languino L R. p27(kipl) acts 
as a downstream effector of and is coexpressed with the 
betalC integrin in prostatic adenocarcinoma. Journal of 
Clinical Investigation. 103(3):321-9, 1999). E-cadherin 
expression is progressively lost during the transformation of 
rat prostate cancer from non-invasive to invasive 
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(Bussemakers M J. van Moorselaar R J. Giroldi L A 
Ichikawa T. Isaacs J T. Takeichi M. Debruyne FM. Schalken 
J A. Decreased expression of E-cadherin in the progression 
of rat prostatic cancer. Cancer Research. 52(10):2916-22, 
1992), and it has also been shown to be an invasion 
suppressor (Lou W. Krill D. Dhir R. Becich M J. Dong J T. 
Frierson H F Jr. Isaacs W B. Isaacs J T. Gao A C. Methy-
lation of the CD44 metastasis suppressor gene in human 
prostate cancer. Cancer Research. 59(10):2329-31, 1999). 
CD44 loss of expression is associated with high metastatic 
ability and transfection of CD44 suppresses metastasis with-
out affecting tumorigenecity of rat prostate cancer cells (Gao 
A C. Lou W. Dong J T. Isaacs J T. CD44 is a metastasis 
suppressor gene for prostatic cancer located on human 
chromosome llp13. Cancer Research. 57(5):846-9, 1997). 
CD44 down-regulation is a prognostic marker for prostate 
cancer (Noordzij MA van Steenbrugge G J. Verkaik N S. 
Schroder F H. van der Kwast TH. The prognostic value of 
CD44 isoforms in prostate cancer patients treated by radical 
prostatectomy. Clinical Cancer Research. 3(5):805-15, 
1997). Human prostate cancer histology is heterogeneous, or 
"multi-focal" in nature (Isaacs JT. Bova GS. Prostate Can-
cer. In The Genetic Basis of Human Cancer (Eds. Vogelstein 
B and Kinzler KW), pp653-60, McGraw-Hill Health Pro-
fessions Division, 1998 and Bova, 1998), with an average of 
five lesions in a patient (Bastacky SI. Wojno KJ. Walsh PC. 
Carmichael M J. Epstein J I. Pathological features of heredi-
tary prostate cancer. Journal of Urology. 153(3 Pt 2):987-92, 
1995). Between the tumor regions of a prostate and within 
a single tumor region, the genetic causes to the cancer are 
heterogeneous and independent as well (Sakr WA Macoska 
J A Benson P. Grignon D J. Wolman S R. Pontes J E. 
Crissman J D. Allelic loss in locally metastatic, multi-
sampled prostate cancer. Cancer Research. 54(12):3273-7, 
1994; Qian J. Bostwick D G. Takahashi S. Borell T J. Herath 
J F. Lieber M M. Jenkins R B. Chromosomal anomalies in 
prostatic intraepithelial neoplasia and carcinoma detected by 
fluorescence in situ hybridization. Cancer Research. 55(22): 
5408-14, 1995; Mirchandani D. Zheng 1. Miller G J. Ghosh 
AK. Shibata D K. Cote R J. Roy-Burman P. Heterogeneity 
in intratumor distribution of p53 mutations in human pros-
tate cancer. American Journal of Pathology. 147(1):92-101, 
1995). In the end, the best predictor of prostate cancer's 
potential to gain invasiveness may be a consideration of a 
number of genes whose expression levels change along the 
course of cancer development, as demonstrated in principle 
by Greene et al. (Greene G F. Kitadai Y. Pettaway CA von 
Eschenbach AC. Buucana C D. Fidler I J. Correlation of 
metastasis-related gene expression with metastatic potential 
in human prostate carcinoma cells implanted in nude mice 
using an in situ messenger RNA hybridization technique. 
American Journal of Pathology. 150(5):1571-82, 1997). 
Hence, expanding the repertory of such genes, including 
both the onco-genes and the suppressor genes, will enhance 
the accuracy and dependability of this approach. As for the 
treatment options of prostate cancer, patients with truly 
organ-confined prostate cancer can be cured by radical 
prostatectomy. Patients with non-organ-confined prostate 
cancers, however, have very low survival rates and the 
current treatments are largely ineffective (Yagoda A Petry-
lak D. Cytotoxic chemotherapy for advanced hormone-
resistant prostate cancer. [Review] [63 refs] Cancer. 71(3 
Suppl): 1098-109, 1993). Breast cancer is the most diag-
nosed cancer in women and the second leading cancer 
related cause of death in women (Greenlee RT, Murray T, 
Bolden S, Wingo PA Cancer statistics, 1999. Ca: a Cancer 
Journal for Clinicians 2000;50:7-33). Breast ductal carci-
6 
noma in situ (hereinafter indicated as DCIS) incidence has 
increased dramatically since 1983 as a result of implement-
ing screening programs (Ernster V L. Barclay J. Increases in 
ductal carcinoma in situ (DCIS) of the breast in relation to 
5 mammography: a dilemma. [Review] [34 refs] Journal of 
the National Cancer Institute. Monographs. 
(22): 151-6, 1997). DCIS is described as a malignant 
growth of epithelial cells within the ducts and lobules of the 
breast, and is believed to be the precursor of all invasive 
10 breast carcinoma. DCIS itself is non-life-threatening; 
however, current treatment options for DCIS include 
masectomy, lumpectomy, radiotherapy or tamoxifen 
(Ernster V L. Barclay J. Increases in ductal carcinoma in situ 
(DCIS) of the breast in relation to mammography: a 
15 dilemma. [Review] [34 refs] Journal of the National Cancer 
Institute. Monographs. (22): 151-6, 1997; Hwang E S. 
Esserman L J. Management of ductal carcinoma in situ. 
[Review] [91 refs] Surgical Clinics of North America. 
79(5):1007-30, viii, 1999). These treatment options for 
20 DCIS are at best controversial due primarily to a lack of 
precision in diagnosis and prognosis of whether the detected 
DCIS will progress to invasive breast cancer and whether 
recurrence is likely after treatment, usually with a high 
percentage being invasive breast cancer (Zaugg K. Bodis S. 
25 Is there a role for molecular prognostic factors in the clinical 
management of ductal carcinoma in situ (DCIS) of the 
breast?. [Review] [ 49 refs] Radiotherapy & Oncology. 
55(2):95-9, 2000). At present, histological grading (nuclear 
grading and whether come do-type necrosis is present) and 
30 the size of the DCIS are used to provide assessments of risk 
of DCIS to progress into invasive breast cancer (Zaugg K. 
Bodis S. Is there a role for molecular prognostic factors in 
the clinical management of ductal carcinoma in situ (DCIS) 
of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology. 
35 55(2):95-9, 2000; Shaker BS. Sloane JP. DCIS grading 
schemes and clinical implications. [Review] [ 40 refs] His-
topathology. 35(5):393-400, 19; van de Vijver M J. Ductal 
carcinoma in situ of the breast: histological classification 
and genetic alterations. [Review] 169 refs] Recent Results in 
40 Cancer Research. 152:123-34, 1998). These parameters are 
far from being adequate for making the most accurate choice 
of treatment, resulting in a choice either overly excessive or 
conservative, in either case, the patient will suffer unneces-
sarily. Molecular markers can help improve our ability to 
45 better diagnose DCIS and stratify treatment options, espe-
cially the molecular markers that, themselves, play a role in 
the progression of DCIS to invasive breast cancer (Zaugg K. 
Bodis S. Is there a role for molecular prognostic factors in 
the clinical management of ductal carcinoma in situ (DCIS) 
50 of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology. 
55(2):95-9, 2000; Silverstein M J. Masetti R. Hypothesis 
and practice: are there several types of treatment for ductal 
carcinoma in situ of the breast?. [Review] [ 53 refs] Recent 
Results in Cancer Research. 152:105-22, 1998). The tum-
55 origenesis process is a multi-step transformation in which 
molecular events escalate to the final stage of invasive 
phenotype (Silverstein MJ. Masetti R. Hypothesis and prac-
tice: are there several types of treatment for ductal carci-
noma in situ of the breast?. [Review] [ 53 refs] Recent 
60 Results in Cancer Research. 152:105-22, 1998). The con-
ventional paradigm of protease involvement in the devel-
opment and progression of cancer has been the assignment 
of a usually negative role to the proteases, such as promoting 
tumor invasion (Mignatti P. Rifkin D B. Biology and bio-
65 chemistry of proteinases in tumor invasion. [Review] [306 
refs] Physiological Reviews. 73(1):161-95, 1993). In turn, 
the conventional paradigm of protease inhibitors in relation 
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to cancer is usually regard of a beneficial effect for the 
presence of these molecules (Kennedy AR. Chemopreven-
tive agents: protease inhibitors. Pharmacol Therapeut 
78:167-209, 1998). Recently, however, the picture of a new 
paradigm is beginning to emerge for several serine proteases 
in breast, prostate, and testicular cancers. A "normal epithe-
lial cell specific-1" (NESl) serine protease was found to be 
down-regulated in breast and prostate cancers, and it func-
tions as a tumor suppressor (Goyal J, Smith KM, Cowan J 
M, Wazer D E, Lee S W, Band V. The role for NESl serine 
protease as a novel tumor suppressor. Cancer Res 
58:4782-4786, 1998). A prostate-specific serine protease, 
prostase (Nelson P S. Gan L. Ferguson C. Moss P. Gelinas 
R. Hood L. Wang K. Molecular cloning and characterization 
of prostase, an androgen-regulated serine protease with 
prostate-restricted expression. Proceedings of the National 
Academy of Sciences of the United States of America. 
96(6):3114-9, 1999), was shown to be expressed in normal 
prostate but not in prostate cancer cell lines DU-145 and 
PC-3. The expression of a testis-specific serine protease, 
testisin, was shown to be lost in testicular cancer through 
either a loss of gene (Hooper JD. Nicol D L. Dickinson J L. 
Eyre HJ. ScarmanAL. Normyle J F. Stuttgen MA Douglas 
M L. Loveland KA Sutherland G R. Antalis T M. Testisin, 
a new human serine proteinase expressed by premeiotic 
testicular germ cells and lost in testicular germ cell tumors. 
Cancer Research. 59(13):3199-205, 1999) or methylation in 
the promoter (Boucaut K, Douglas M, Clements J, Antalis T. 
The serine proteinase testisin may act as a tumor and/or 
growth suppressor in the testis and may be regulated by 
DNA methylation. Cancer Genetics and Tumor Suppressor 
Genes, Cold Spring Harbor Laboratory, 2000). Further, 
transfection of human testicular cancer cells with a testisin 
cDNAreduced the tumor growth of xenografts of these cells 
in nude mice, suggesting a tumor suppressor function for 
testisin (Boucaut K, Douglas M, Clements J, Antalis T. The 
serine proteinase testisin may act as a tumor and/or growth 
suppressor in the testis and may be regulated by DNA 
methylation. Cancer Genetics and Tumor Suppressor Genes, 
Cold Spring Harbor Laboratory, 2000). The testisin serine 
protease is potentially membrane-bound as suggested by its 
structure and confirmed by immunohistochemistry gene 
(Hooper JD. Nicol D L. Dickinson J L. Eyre HJ. Scarman 
AL. Normy le J F. Stungen MA Douglas M L. Loveland K 
A Sutherland GR. Antalis TM. Testisin, a new human serine 
proteinase expressed by premeiotic testicular germ cells and 
lost in testicular germ cell tumors. Cancer Research. 59(13): 
3199-205, 1999.) Prostasin serine protease is an acidic 
protein (pl 4.5-4.8) of approximately 40 kDa in molecular 
mess (Yu JX. Chao L. Chao J. Prostasin is a novel human 
serine proteinase from seminal fluid. Purification, tissue 
distribution, and localization in prostate gland. Journal of 
Biological Chemistry. 269(29):18843-8, 1994). It is pre-
dominantly made in the prostate gland (-146 ng/mg 
protein), with lesser amounts (2-6 ng/mg protein) also found 
in the bronchi, colon, kidney, liver, lung, pancreas, and the 
salivary glands (Yu JX. Chao L. Chao J. Prostasin is a novel 
human serine proteinase from seminal fluid. Purification, 
tissue distribution, and localization in prostate gland. Journal 
of Biological Chemistry. 269(29):18843-8, 1994). Prostasin 
8 
of Biological Chemistry. 269(29):18843-8, 1994; (Yu JX. 
Chao L. Chao J. Molecular cloning, tissue-specific 
expression, and cellular localization of human prostasin 
mRNA. Journal of Biological Chemistry. 270(22):13483-9, 
5 1995). Molecular cloning of a full-length human prostasin 
cDNA revealed that its predicted amino acid residue 
sequence contains a carboxyl-terminal hydrophobic region 
that can potentially anchor the protein on the membrane (Yu 
JXChao L. Chao J. Molecular cloning, tissue-specific 
10 expression, and cellular localization of human prostasin 
mRNA. Journal of Biological Chemistry. 270(22):13483-9, 
1995). At the amino acid level, prostasin is similar to plasma 
kallikrein, coagulation factor XI, hepsin, plasminogen, 
acrosin, prostase, and, in particular, testisin (sharing 44% 
15 sequence identity) [Nelson PS. Gan L. Ferguson C. Moss P. 
Gelinas R. Hood L. Wang K. Molecular cloning and char-
acterization of prostase, an androgen-regulated serine pro-
tease with prostate-restricted expression. Proceedings of the 
National Academy of Sciences of the United States of 
20 America 96(6):3114-9, 1999; Hooper J D. Nicol D L. 
Dickinson J L. Eyre HJ. ScarmanAL. Normy le J F. Stuttgen 
MA Douglas M L. Loveland KA Sutherland G R. Antalis 
T M. Testisin, a new human serine proteinase expressed by 
premeiotic testicular germ cells and lost in testicular germ 
25 cell tumors. Cancer Research. 59(13):3199-205, 1999; Yu 
JX. Chao L. Chao J. Molecular cloning, tissue-specific 
expression, and cellular localization of human prostasin 
mRNA. Journal of Biological sodium channel-activating 
protease (CAPl) was shown to be highly homologous to 
30 human prostasin as well (sharing 53% sequence identity at 
the amino acid level) (Vallet V. Chraibi A Gaeggeler H P. 
Horisberger JD. Rossier B C. An epithelial serine protease 
activates the amiloride-sensitive sodium channel. Nature. 
389(6651):607-10, 1997). Prostasin is encoded by a single-
35 copied gene, which is located on human chromosome 16pl 
1.2 (Yu JX. Chao L. Ward D C. Chao J. Structure and 
chromosomal localization of the human prostasin (PRSS8) 
gene. Genomics. 32(3):334-40,1996). The secreted prosta-
sin cleaves synthetic substrates in vitro preferentially at the 
40 carboxyl-terminal side ofArg residue, and is thus considered 
a trypsin-like serine protease (Yu JX. Chao L. Chao J. 
Prostasin is a novel human serine proteinase from seminal 
fluid. Purification, tissue distribution, and localization in 
prostate gland. Journal of Biological Chemistry. 269(29): 
45 18843-8, 1994). The physiological function of prostasin, 
however, has remained unknown. By comparing gene 
expression of normal tissues, pre-invasive cancer, and inva-
sive cancer, it would be highly advantageous to discover 
molecular markers that display a differential expression 
50 pattern between the pre-invasive and the invasive pheno-
types and use these markers for a more precise diagnosis and 
prognosis of prostate and/or breast cancers. With the 
enhanced precision in diagnosis and prognosis, treatment 
options for patients with DCIS could then be stratified. 
55 Those with low risks of developing invasive breast cancer 
will have a higher confidence in choosing breast-conserving 
options, while those at high risks will ponder more aggres-
sive options with the necessary follow-up treatments. 
Similarly, those males with low risks of developing invasive 
60 prostate cancer will have a higher confidence in choosing 
prostate-conserving options, while those at high risks will 
ponder more aggressive options with the necessary follow-
up treatments. 
is secreted in the prostatic fluid, and can be detected in the 
semen (-9 µg/ml). Prostasin expression is localized to the 
epithelial cells of human prostate gland by in situ hybrid-
ization histochemistry using an antibody or an anti-sense 
RNA probe (Yu J X. Chao L. Chao J. Prostasin is a novel 65 
human serine proteinase from seminal fluid. Purification, 
tissue distribution, and localization in prostate gland. Journal 
SUMMARY OF THE INVENTION 
The first objective of the present invention is to reduce 
deficiencies in the prior art with specific regard to differen-
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tial diagnosis of invasive prostate and breast cancers and to 
treatment of invasive and metastatic prostate and breast 
cancers. 
10 
FIG. 2 is a diagrammatic representation of the analysis of 
prostasin indicative of the absence or existence, or of the 
invasiveness of human mammary carcinoma 
The second objective of the present invention is to pro-
vide a new marker for prostate and breast cancer. 
The third objective of the invention is to provide as a drug 
to patients with carcinoma of the prostate via delivery of a 
functional prostasin gene. 
FIG. 3 shows human prostasin expression in prostate 
5 epithelial cells. 
The fourth objective of the invention is to provide as a 
drug to patients with carcinoma of the prostate via delivery 10 
of a functional prostasin cDNA. 
The fifth objective of the invention is to provide as a drug 
to patients with carcinoma of the breast via delivery of a 
functional prostasin gene. 
The sixth objective of the invention is to provide as a drug 15 
to patients with carcinoma of the breast via delivery of a 
functional prostasin cDNA. 
FIG. 4A shows immunohistochemical detection of pros-
tasin protein in benign human prostate tissues. 
FIG. 4B is an enlarged view of the boxed region of FIG. 
4A. 
FIG. 4C shows immunohistochemistry of benign human 
prostate tissues with prostasin antibody omitted in the 
procedures, no epithelial cells displayed any staining. 
FIG. 4D is an enlarged view of the boxed region of FIG. 
4C. 
FIG. 4E shows immunohistochemistry of human prostate 
tumor with prostasin antibody omitted in the procedures, no 
epithelial cells displayed any staining. This invention identifies prostasin serine protease as a 
potential marker, and as a tumor invasion suppressor for 
prostate and breast cancers and thus provides methods (a), 
(b), .and (c) of determining invasiveness levels of human 
carcmomas: 
FIG. 4F shows immunohistochemical detection of pros-
20 tasin protein in benign human prostate tissue surrounded by 
(a) using prostasin protein levels, comprising the steps of: 
sampling a human carcinoma tissue; determining pros-
~~~Fer~~~~ei~/e~;~~y~~g th:n h~:~~n~t~~~~T~e~:~~~: 25 
antibody to said tissue wherein the reagent-antibody 
becomes bound to prostasin protein in said tissue, and 
determining invasiveness of the human carcinoma tis-
sue based on the prostasin protein levels:. or 
(b) using prostasin mRNA levels, comprising the steps of: 30 
sampling a human carcinoma tissue; determining pros-
tasin mRNA levels in the human carcinoma tissue 
preferably by applying prostasin-specific anti-sense 
RNA probes in an in situ hybridization to determine the 
prostasin mRNA levels in the separated human carci- 35 
noma tissue the determination of the prostasin mRNA 
levels in the separated human carcinoma sample tissue; 
to make possible and determining invasiveness of the 
human carcinoma tissue based on the prostasin mRNA 
levels; or 40 
prostate carcinomas. 
FIG. 4G shows immunohistochemical detection of pros-
tasin protein in Gleason grade 2 prostate tumor. 
FIG. 4H is an enlarged view of the boxed region of FIG. 
4G. 
FIG. 4I shows immunohistochemical detection of prosta-
sin protein in Gleason grade 3 prostate tumor. 
FIG. 41 is an enlarged view of the boxed region of FIG. 
41. 
FIG. 4K shows immunohistochemical detection of pros-
tasin protein in Gleason grade 4 prostate tumor. 
FIG. 4L is an enlarged view of the boxed region of FIG. 
4K. 
FIG. 5 shows human prostasin expression in human breast 
cancer cell lines. 
FIG. 6 shows promoter hypermethylation of the human 
prostasin gene in human prostate and breast cancer cell lines. 
FIG. 7 shows prostasin protein expression and in vitro 
invasive properties of the DU-145 and the PC-3 transfec-
tants. 
FIG. 8 shows prostasin protein expression and in vitro 
invasive properties of the MDA-MB-231 and the MDA-
45 MB-435s transfectants. 
(c) using prostasin gene promoter DNA methylation 
levels, comprising the steps of: sampling a human 
carcinoma tissue; determining prostasin gene promoter 
DNA methylation levels in the human carcinoma 
tissue, preferably by applying prostasin-promoter-
specific oligonucleotide primers in a PCR to determine 
the prostasin gene promoter DNAmethylation levels in 
the sampled human carcinoma tissue and determining 
invasiveness of the human carcinoma tissue based on 
the prostasin gene promoter DNA methylation levels, 50 
FIG. 9a Is a schematic illustration of the promoter-exon 
region of the prostasin gene. 
FIG. 9b shows a genomic Southern blot analysis of DNA 
from NHMEC and human breast cancer cell lines. 
FIG. 9c shows a genomic Southern blot analysis of 
MDA-MB-231 and MDA-MB-435s cells following dem-
ethylation. 
as well as a method of treating invasive human carcino-
mas comprising the steps of: incorporating human 
prostasin nucleic acid into a selected gene delivery 
vector nucleic acid to form a recombinant nucleic acid; 
preferably wherein the nucleic acid includes a gene or 
cDNA delivering the recombinant nucleic acid into a 
human carcinoma; and reducing invasiveness of the 
human carcinoma. 
FIG. 10 shows DNA sequence and the deduced ammo 
55 acid sequence of the PRSS8 (prostasin) gene. 
Further objects and advantages of this invention will be 
apparent from the following detailed description of a pres- 60 
ently preferred embodiment, which is illustrated schemati-
cally in the accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURE 
FIG. 1 is a diagrammatic representation of the analysis of 65 
prostasin indicative of the absence or existence, or of the 
invasiveness of human prostate carcinoma. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
Before explaining the disclosed embodiment of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangement shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
Using RT-PCR and western blot analyses, prostasin pro-
tein and mRNA expression were found in normal human 
prostate epithelial cells and the human prostate cancer cell 
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the potential invasiveness of prostate tumors. The support-
ing evidence came from our findings that two invasive 
human prostate cancer cell lines DU-145 and PC-3 do not 
express prostasin while normal prostate epithelial cells and 
line LNCaP, but discovered not present in the highly inva-
sive human prostate cancer cell lines DU-145 and PC-3. 
Immunohistochemistry studies of human prostate cancer 
specimens revealed a down-regulation of prostasin in high-
grade tumors. 5 a non-invasive prostate cancer cell line LNCaP express both 
the prostasin mRNA and protein. Using RT-PCR and western blot analyses, prostasin pro-
tein and mRNA expression were found in a non-invasive 
human breast cancer cell line, MCF-7, while invasive human 
breast cancer cell lines MDA-MB-231 and MDA-MB-435s 
were also discovered not to express either the prostasin 
protein or the mRNA. A non-invasive human breast cancer 
cell line, MDA-MB-453, was shown to express prostasin 
mRNA but not prostasin protein. Examination of the pros-
tasin gene promoter in the human prostate and breast cancer 
cell lines by Southern blot analysis revealed heterogeneous 
methylation of the promoter in DU-145, PC-3 and MDA-
MB-453 cells, and homogeneous methylation of the pro-
moter in MDA-MB-231 and MDA-MB-435s cells. The 
prostasin gene promoter in normal human prostate epithelial 
cells, the LNCaP and the prostasin gene promoter in the 
human prostate and breast cancer cell lines by Southern blot 
analysis revealed heterogeneous methylation of the pro-
moter in DU-145, PC-3 and MDA-MB-453 cells, and homo-
geneous methylation of the promoter in MDA-MB-231 and 
MDA-MB-435s cells. The prostasin gene promoter in nor- 25 
mal human prostate epithelial cells, the LNCaP and the 
MCF-7 cells was shown to be unmethylated. Transfection of 
DU-145 and PC-3 cells with a full-length human prostasin 
cDNArestored prostasin expression and reduced the in vitro 
invasiveness by 68% and 42%, respectively. Transfection of 30 
MDA-MB-231 and MDA-MB-435s cells with a full-length 
human prostasin cDNA restored prostasin expression and 
reduced the in vitro invasiveness by 50% for either cell line. 
Cell proliferation was unaffected by re-expression of pros-
tasin. Our data indicate that prostasin is implicated in normal 35 
prostate biology and its down-regulation in prostate cancer, 
and its absence in invasive prostate and breast cancer cell 
lines indicates increased invasiveness. Our results also indi-
cate that delivering a functional human prostasin gene to 
invasive prostate and breast cancers can reduce the inva- 40 
s1veness. 
For a facile understanding of the invention embodied 
herein, reference should now be made to FIGS. 1and2. FIG. 
Refer now to FIG. 3 which shows human prostasin 
expression in prostate epithelial cells. By means of western 
blot analysis (upper panel), prostasin (as a 40-kDa band) was 
10 detected in normal human prostate epithelial cells (CC-
2555) and the LNCaP cells, but not in the DU-145 or PC-3 
cells. An equal amount of total protein (100 µg) was loaded 
for each sample. At the mRNA level, human prostasin 
mRNA (via a 232-bp amplified DNA band) was detected in 
15 normal prostate epithelial cells (CC-2555) and the LNCaP 
cells, but not in the DU145 or PC-3 cells as analyzed by 
RT-PCR/Southern blot hybridization (middle panel). 
Co-amplification of a 556-bp human ~-actin message (as 
shown in the gel photograph in the lower panel) confirmed 
20 the quality and the quantity of the RNA applied in each 
RT-PCR. 
Expression of prostasin protein is reduced in high-grade 
human prostate tumor. Prostatectomy specimens from 39 
patients (128 sections) were subjected to immunohistochem-
istry using a prostasin-specific antibody. Overall, in non-
tumor or benign prostate epithelia, 89.0% of the examined 
areas demonstrated positive staining for prostasin protein 
and 11.0% were considered negative (based on the scoring 
system used for HercepTest™, DAKO Corporation, 
Carpinteria, CA). In all tumor specimens that were 
examined, prostasin was detected in 93.3% of the low 
Gleason grade areas (~grade 2), 44.4% of Gleason grade 3 
areas, 21.1 % of Gleason grade 4 areas, but not in Gleason 
grade 5 areas (data summarized in Table 1). The mean 
prostasin immunostaining score was found significantly 
decreased in high-grade prostate tumors as compared to 
non-tumor areas (ANOVA, p<0.0001). 
Representative staining images of non-tumor (benign) 
areas and prostate tumor areas are shown in FIGS. 4a-4l, 
which provides immunohistochemical detection of prostasin 
protein in tissues. Paraffin-embedded human prostate sec-
tions were stained for prostasin protein expression evalua-
tion using a specific antibody as described (Yu JX. Chao L. 
Chao J. Prostasin is a novel human serine proteinase from 
45 seminal fluid. Purification, tissue distribution, and localiza-
tion in prostate gland. Journal of Biological Chemistry. 
269(29):18843-8, 1994). Prostasin positive staining (brown 
color) was detected in the cytoplasm and apical membrane 
1 sets forth a schematic for determining if a male has 
prostate cancer. Human blood 10 is taken from the male and 
analyzed for the presence of prostasin serine protease 14. If 
NO 12 prostasin is found, there is probably little or no 
cancer. If there is a presence YES 16 of prostasin serine 
protease 14, there is prostate cancer. If a biopsy of the 
prostate gland 20 is analyzed for the presence of a normal 50 
amount YES 22 of prostasin serine protease 14, there is no 
cancer or there is non-invasive cancer. If there is NO 24 or 
Reduced 26 amount of prostasin serine protease 14, there is 
in non-tumor or benign epithelial cells. 
The prostasin protein was detected in the cytoplasm and 
on the plasma membrane (apical) of benign epithelial cells 
lining the secretory lumen as well as in the secretion inside 
the lumen (FIGS. 4A and 4B, score 3, or+++), confirming 
the results of (Yu JX. Chao L. Chao J. Prostasin is a novel 
human serine proteinase from seminal fluid. Purification, 
tissue distribution, and localization in prostate gland. Journal 
invasive cancer. 
FIG. 2 sets forth a schematic for determining if a female 55 
has breast cancer. Human blood 100 is taken from the female 
and analyzed for the presence of prostasin serine protease 
140. If NO 120 prostasin is found, there is prospectively no 
cancer. If there is a presence YES 160 of prostasin serine 
protease 140, there is breast cancer. If a biopsy of the breast 
200 is analyzed for the presence of YES 220 of prostasin 
serine protease 140, there is no invasive cancer but may be 
non-invasive cancer. If there is NO 240 or Reduced 260 
amount of prostasin serine protease 140, there is invasive 
cancer. 
The levels of prostasin protein in the epithelial cells of the 
human prostate gland can be used as a diagnostic marker for 
of Biological Chemistry. 269(29):18843-8, 1994). When a 
pre-immune rabbit serum was used in place of the prostasin 
antiserum, no staining was observed in either the non-tumor 
60 epithelia (FIGS. 4C and 4D) or tumor epithelia (FIG. 4E). 
Tumor epithelia displayed various degrees of prostasin 
immunostaining as shown in FIGS. 4F-4L. In Gleason grade 
1-2 tumors, moderate prostasin staining is seen in the 
cytoplasm and on the plasma membrane of some epithelial 
65 cells, as well as in the secretion in the lumen (FIGS. 4G and 
4H, score 2, or ++ ). In Gleason grade 3 tumors, a lesser 
number of epithelial cells displayed the moderate level 
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prostasin staining (FIGS. 4I and 41). In Gleason grade 4 
tumors, most epithelial cells did not show any prostasin 
staining, while some prostasin staining can be seen in rare, 
sporadic tumor cells (FIGS. 4K and 4L, as indicated by the 
arrow, score 0). Genetically, prostate tumors are heteroge- 5 
neons and multi-focal in nature, in that one patient's gross-
anatomy tumor comes from multiple initial lesions which 
are caused by different initial transformation events and 
progress to different stages by different ensuing transforma-
tions (Isaacs J T. Bova GS. Prostate Cancer. In The Genetic 10 
Basis of Human Cancer (Eds. Vogelstein B and Kinzler 
KW), pp653-60, McGraw-Hill Health Professions Division, 
1998). The Gleason grading, when used as a percentage of 
each cancer occupied by Gleason grade o/s areas, is inde-
pendently associated with prostate cancer progression 15 
(Stamey T A, McNeal J E, Yemoto C M, Sigal B M, 
Johnstone I M. Biological determinants of cancer progres-
sion in men with prostate cancer. JAMA 281:1395-1400, 
1999). We found a significant decrease of prostasin expres-
sion in the high-grade, i.e., the more progressively trans- 20 
formed tumors. 
As earlier indicated, FIG. 5 shows human prostasin 
expression in human breast cancer cell lines. By means of 
western blot analysis (upper panel), prostasin (as a 40-kDa 
band) was detected in MCF-7 cells, but not in MDA- 25 
MB453, MDA-MB-231, or MDA-MB-435s cells. An equal 
amount of total protein (100 µg) was loaded for each sample. 
At the mRNA level, human prostasin mRNA (via a 232-bp 
amplified DNA band) was detected in MCF-7 and MDA-
MB453 cells, but not in the MDA-MB-231 or MDA-MB- 30 
435s cells as analyzed by RT-PCR/Southern blot hybridiza-
tion (lower panel). 
14 
methylation-insensitive enzyme Msp I to yield a 951-bp 
fragment for all DNA samples. The methylation-sensitive 
isoschizomer Hpa II yields the 951-bp fragment in the 
CC-2555 (normal prostate epithelial cells), the LNCaP, and 
the MCF-7 samples, indicating the hypomethylated or unm-
ethylated state of the prostasin promoter in these cells. For 
DU-145, PC-3, and MDA-MB453 DNA, both the 951-bp 
and the 1,275-bp fragments are generated in the 
methylation-sensitive digestion, suggesting incomplete 
methylation (one of two or more chromosomes) or clonal 
methylation in a sub-population of cells. For the MDA-MB-
231 and MDA-MB-435, however, the Hpa II digestion did 
not yield the 951-bp but rather gave the 1,275-bp fragment. 
This homogeneous methylation pattern indicates that the 
Msp l/Hpa II site, at location-96 (relative to the transcription 
initiation site) of the prostasin promoter, is methylated 
(hypermethylated) in these DNA samples. 
Signal intensity variation may be attributed to aneuploidy. 
(In addition to the Hpa II site at base number 1326/-96 
shown in FIG. 6, example 1 and 2 are provided, more 
extensively detailing the other prostasin gene promoter 
methylated sites and experimental methods for determining 
them. Such sites have been located at bp 615/-807, 1,102/-
320, 1,156/-266, 1,326/-96 and 1,445/+24. Nomenclature 
used in describing the nucleic acid sequences of the pros-
tasin gene are described by Yu, et al in Structure and 
Chromosomal localization of the human prostasis (PRSS8) 
gene. Genomics 1996:32 pp. 334-40); page 336 of the Yu, 
et al reference is incorporated as FIG. 10 in the description 
of the present invention. 
Prostasin mRNAexpression is seen absent in two invasive 
human breast cancer cell lines while two non-invasive breast 
cancer cell lines express prostasin mRNA or protein. Analy-
sis of prostasin expression in human breast cancer cell lines 
showed that the non-invasive MCF-7 and MDA-MB-453 
cells express the prostasin mRNA while the highly invasive 
MDA-MB-231 and MDA-MB-435s cells do not express the 
prostasin mRNA (see FIG. 5). Expression of prostasin 
mRNA in normal human breast can be demonstrated by the 
presence of two GenBank™ normal human breast EST 
sequences coding for prostasin (Accession numbers 
R48653, and R48557). The MCF-7 cells also express the 
prostasin protein as determined by western blot analysis 45 
(again see FIG. 5). Prostasin down-regulation in prostate or 
breast cancer can be caused by promoter methylation or 
gene-specific mutation. Prostasin expression decreases with 
increasing prostate cancer grade and is absent in invasive 
prostate and breast cancer cell lines. The chromosomal locus 50 
where the human prostasin gene is, 16pll.2, however, is not 
known to be an LOH hot-spot in prostate cancer or in breast 
cancer. Epigenetic events (such as DNA methylation) may 
An examination of the prostasin gene promoter region for 
DNA methylation differences among human prostate and 
breast cancer cell lines has been made (see FIG. 6). We 
found that cells that express prostasin, normal prostate 
35 epithelial, LNCaP, and MCF-7, are unmethylated in the 
prostasin promoter while MDA-MB-453 showed heteroge-
neous prostasin promoter methylation. For cells that do not 
express prostasin, DU-145 and PC-3 showed heterogeneous 
prostasin promoter methylation while MDA-MB-231 and 
40 MDA-MB-435 showed homogeneous hypermethylation in 
the promoter region of the prostasin gene. 
be an alternative mechanism of loss of expression for tumor 
suppressors or invasion suppressors. Refer now to FIG. 6 55 
which shows promoter hypermethylation of the human 
prostasin gene in human prostate and breast cancer cell lines. 
Genomic DNA (5 µg) from the various cell lines (as indi-
cated in the figure) were digested with the following restric-
tion enzyme combinations, Xho l/BamH I (X/B, flanking 60 
cuts of the methylation-sensitive site), Xho I/BamH l/Msp I 
(X/B/M), or Xho l/BamH I/Hpa II (X/B/H). The digests 
were resolved in a 0.8% agarose gel and transferred to an 
Immobilon-N membrane for hybridization with a nick-
translated prostasin promoter probe (bases 703-1,649 of the 65 
prostasin gene sequence U33446). The probe detects a 
promoter fragment of 1,275 bp, which is cut by the 
Two human prostate cancer cell lines that do not express 
prostasin, the highly invasive DU-145 and PC-3, show 
heterogeneous methylation in the promoter region of the 
prostasin gene. The result suggests that at least one of the 
two (or more) chromosome 16's of these cell lines is 
methylated at the prostasin gene locus. The prostasin gene 
on the unmethylated chromosome may contain mutations 
that silenced the expression. An alternative explanation for 
the heterogeneous methylation pattern is that the methyla-
tion occurs in clonal cell populations, however, the lack of 
detectable prostasin mRNA in our RT-PCR-Southern blot 
analysis in the DU-145 and PC-3 cells argues against this 
possibility. 
The significance of the finding on prostasin gene promoter 
hypermethylation in prostate or breast cancer is that the 
measurement of prostasin down-regulation as a cancer 
marker may be achieved by using a binary assay (yes-or-no), 
instead of a gradually decreasing quantity in the immuno-
histochemistry assay (which is quite arbitrary). 
Re-expression of human prostasin protein in invasive 
human prostate and breast cancer cells reduces invasiveness 
in vitro. At this point, reference should be made to FIG. 7 
which shows the prostasin protein expression and in vitro 
invasive properties of the DU-145 and the PC-3 transfec-
tants. DU-145 or PC-3 cells transfected with either a vector 
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DNA (labeled as "vector") or a prostasin cDNA construct 
(labeled as "prostasin") were analyzed by a western blot 
analysis using a prostasin-specific antibody (upper panel) or 
subjected to an in vitro Matrigel chemoinvasion assay 
(lower panel) as described in (Liu DF. Rabbani SA Induc-
tion of urinary plasmiinogen activator by retinoic acid 
results in increased invasiveness of human prostate cancer 
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed 
human prostasin protein (a 40-kDa band) was detected in the 
prostasin cDNA-transfected DU-145 or PC-3 cells, but not 
16 
firmed by western blot analysis (FIG. 8, upper panel). In in 
vitro Matrigel chemoinvasion assays, the invasiveness of 
either cell lines expressing human prostasin was reduced by 
50% as compared to the vector-transfected controls (FIG. 8, 
5 lower panel). 
Taken together, the foregoing evidences linking prostasin 
level reduction or protasin absence to the invasiveness of 
prostate and breast cancer cell lines, or linking prostasin 
expression to reduced invasiveness. The evidence qualifies 
10 prostasin as an invasion suppressor, which thus is a marker 
for diagnosis of invasiveness of prostate and breast cancers, 
or as a therapeutic agent to treat invasive prostate and breast 
cancers. 
in the vector-transfected cells. In the Matrigel chemoinva-
sion assay, the vector-transfected cells are expressed as 
being 100% invasive (solid bar), the open bar represents the 
relative invasiveness of the human prostasin cDNA-
transfected cells. The data were analyzed by a Student t-test 15 
using the StatView software (Abacus Concepts, Inc., 
Berkeley, Calif.). 
Pathological grading by the Gleason system is performed 
after either surgery or biopsy, both highly invasive 
procedures, while blood tests such as that for the PSA 
prostate cancer marker can offer the hope of accurate diag-
nosis and prognosis without the harm of an invasive proce-
dure. In practice, however, single markers suffer from an 
It can be seen that Polyclonal DU-145 and PC-3 cells 
transfected with the human prostasin cDNA (designated 
DU-145/Pro, and PC-3/Pro, respectively) were confirmed to 20 
express the human prostasin protein, as shown in the western 
blot analysis of the cell lysate (FIG. 7, upper panel). The 
vector-transfected cells, designated DU-145/Vector or PC-3/ 
Vector, respectively, were used as negative control in the 
western blot. A further examination of the DU-145/Pro and 25 
the PC-3/Pro cells by immunocytochemistry confirmed that 
100% of the cells expressed the prostasin protein (data not 
shown). In in vitro Matrigel chemoinvasion assays (FIG. 7, 
lower panel), the invasiveness of DU-145/Pro cells was 
determined to be at 32% of that of DU-145Nector cells (or, 30 
the reduction of invasiveness was at 68%). The invasiveness 
intrinsic limitation that the "positive" identifications are not 
always confirmed for the "diagnosed" disease. Biopsy is still 
required for a true positive identification of prostate cancer 
even in the case of the application of the PSA prostate cancer 
marker (Catalana W J. Partin AW. Slawin KM. Brawer M 
K. Flanigan R C. Patel A Richie J P. deKemion J B. Walsh 
P C. Scardino P T. Lange P H. Subong E N. Parson R E. 
Gasior G H. Loveland K G. Southwick P C. Use of the 
percentage of free prostate-specific antigen to enhance dif-
ferentiation of prostate cancer from benign prostatic disease: 
a prospective multicenter clinical trial [see comments]. 
JAMA 279(19):1542-7, 1998). As stated above, it has been 
of PC-31Pro cells was determined to be at 58% of that of 
PC-3Nector cells (or, the reduction of invasiveness was at 
42%). We performed in vitro cell proliferation assays on 
DU-145/Pro vs. DU-145Nector cells, and on PC-3/Pro vs. 
PC-3/Vector cells, but did not observe any difference 
between the growth rates of the prostasin cDNA-transfected 
or the vector-transfected cells over an 8-day period (data not 
shown). 
Forced re-expression of human prostasin in two invasive 
human breast cancer cell lines reduced invasiveness. A 
full-length human prostasin cDNA under the control of an 
RSV promoter was transfected into the invasive breast 
cancer MDA-MB-231 and MDA-MB-435 cells. Reference 
should be made to FIG. 8 which shows prostasin protein 
expression and in vitro invasive properties of the MDA-
MB-231 and the MDA-MB-435s transfectants. MDA-MB-
231 and MDA-MB-435s cells transfected with either a 
vector DNA (labeled as "vector") or a prostasin cDNA 
construct (labeled as "prostasin") were analyzed by a west-
ern blot analysis using a prostasin-specific antibody (upper 
panel) or subjected to an in vitro Matrigel chemoinvasion 
assay (lower panel) as referenced in (Liu DF. Rabbani SA 
Induction of urinary plasminogen activator by retinoic acid 
results in increased invasiveness of human prostate cancer 
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed 
human prostasin protein (a 40-kDa band) was detected in the 
prostasin cDNA-transfected MDA-MB-231 and MDA-MB-
435s cells, but not in the vector-transfected cells. In the 
Matrigel chemoinvasion assay, the vector-transfected cells 
are expressed as being 100% invasive (solid bar), the open 
bar represents the relative invasiveness of the human pros-
tasin cDNA-transfected cells. The data were analyzed by a 
Student t-test using the StatView software (Abacus 
Concepts, Inc., Berkeley, Calif.). 
Stable, polyclonal, episomal transfectants were obtained 
and the expression of human prostasin protein was con-
demonstrated in principle that many markers used in a 
multivariate approach may provide a highly accurate diag-
nosis (Greene G F. Kitadai Y. Pettaway Calif. von Eschen-
35 bach AC. Bucana C D. Fidler I J. Correlation of metastasis-
related gene expression with metastatic potential in human 
prostate carcinoma cells implanted in nude mice using an in 
situ messenger RNA hybridization technique. American 
Journal of Pathology. 150(5):1571-82, 1997). From the 
40 standpoint of prostate cancer genetics, the multivariate 
approach is well supported by our current understanding. A 
serine protease structurally and genetically related to the 
PSA, the hK2 (human glandular kallikrein 2) has shown 
some promise of joining the list of markers applicable for 
45 prostate cancer diagnosis (Saedi M S. Hill T M. Kuus-
Reichel K. Kumar A Payne J. Mikolajczyk SD. Wolfert R 
L. Rittenhouse H G. The precursor form of the human 
kallikrein 2, a kallikrein homologous to prostate-specific 
antigen, is present in human sera and is increased in prostate 
50 cancer and benign prostatic hyperplasia. Clinical Chemistry. 
44(10):2115-9, 1998). Structurally and in prostate gland 
biology, prostasin shares many common characteristics with 
both PSA and hK2, as being a secreted serine protease made 
in large abundance in prostate epithelial cells (Yu JX. Chao 
55 L. Chao J. Prostasin is a novel human serine proteinase from 
seminal fluid. Purification, tissue distribution, and localiza-
tion in prostate gland. Journal of Biological Chemistry. 
269(29):18843-8, 1994; Yu JX. Chao L. Chao J. Molecular 
cloning, tissue-specific expression, and cellular localization 
60 of human prostasin mRNA Journal of Biological Chemistry. 
270(22):13483-9, 1995). While high-grade prostate cancer 
cells produce less PSA protein than normal prostate cells or 
low-grade prostate cancer cells (Hakalahti L. Vihko P. 
Henttu P. Autio-Harmainen H. Saini Y. Vihko R. Evaluation 
65 of PAP and PSAgene expression in prostatic hyperplasia and 
prostatic carcinoma using northern-blot analyses, in situ 
hybridization and immunohistochemical stainings with 
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monoclonal and bispecific antibodies. International Journal 
18 
The preferred methods of separating sampled human 
carcinoma tissue from neighboring normal tissues is by laser 
capture micro-dissection. 
The following examples are provided for the purpose of 
5 illustration and not limitation: 
of Cancer. 55(4):590-7, 1; Sakai H. Yogi Y. Minami Y. 
Yushita Y. Kanetake H. Saito Y. Prostate specific antigen and 
prostatic acid phosphatase immunoreactivity as prognostic; 
Sakai H. Yogi Y. Minami Y. Yushita Y. Kanetake H. Saito Y. 
Prostate specific antigen and prostatic acid phosphatase 
immunoreactivity as prognostic), the serum PSA levels in 
prostate cancer patients increase due to tissue damage 
caused by invasive cancer (Rittenhouse H G. Finlay J A 
Mikolajczyk SD. Partin AW. Human Kallikrein 2 (hK2) and 
10 
prostate-specific antigen (PSA): two closely related, but 
distinct, kallikreins in the prostate. [Review] [ 457 refs] 
Critical Reviews in Clinical Laboratory Sciences. 35( 4): 
275-368, 1998). By comparison, we also believe prostasin 
is in the circulation of prostate cancer patients. As a result, 
a blood test for the circulating prostasin to indicate the 15 
presence and/or the stage of prostate cancer would be highly 
useful. (as illustrated in FIG. 1). In principal, the feasibility 
of a blood test based on prostasin detection to indicate 
cancer has been demonstrated by Berteau et al. (1999). 
These authors (Berteau P. Laribi Eschwege P. Lebars I. 20 
Dumas F. Benoit G. Lorie S. Prostasin mRNA to detect 
Example 1 
Prostasin Promoter DNA Methylation 
Cell Culture Maintenance 
All cell culture media, sera and supplements were pur-
chased from Life Technologies (Gaithersburg, Md.) except 
for those otherwise noted 
A normal human mammary epithelial cell primary culture 
(catalog number CC-255) was obtained from Clonetics (San 
Diego, Calif.) and maintained in the mammary epithelial 
basal medium (supplemented with bovine pituitary extract, 
recombinant human epidermal growth factor, bovine insulin 
and hydrocortisone) according to the suppliers protocols. 
The Culture was kept at 37° C. with 5% C02 and used for 
experiments at the 9th overall passage. 
Human breast carcinoma cell lines MCF-7, MDA-MB_ 
453, MDA-MB-231 and MDA_MB-435 were obtained 
from the American Type Culture Collection (ATCC, 
Manassas, Va.). The MCF-7 cells were maintained in 
DMEM supplemented with 10% FBS and kept at 37 for 
prostate cells in blood of cancer patients. Clinical and 
Chemical Laboratory Medicine 37 (SS): SI 19, 1999), 
demonstrated a highly promising potential of using prostasin 
as a marker to detect circulating prostate epithelial cells, a 
sign of prostate tissue damage caused by invasive prostate 
cancer leading to the dissemination of prostate epithelial 
cells into the circulation. It is expected that a blood test for 
circulating prostasin to indicate the presence and/or the stage 
25 experiments at the 9th overall passage. 
Human breast carcinoma cell lines MCF-7, MDA-MB_ 
453, MDA-MB-231 and MDA_MB-435 were obtained 
from the American Type Culture Collection (ATCC, 
Manassas, Va.). The MCF-7 cells were maintained in 
of breast cancer would be highly useful. (as illustrated in 
FIG. 2). 
In summary of the invention, it has been taught herein 
that: protein prostasin as well as its MRA levels and its gene 
promoter DNA methylation levels can be used to determine 
the invasiveness level of human carcinomas; and, provide a 
method of treating invasive human carcinomas by delivery 
thereto of a recombinant nucleic acid formed by a human 
prostasin nucleic acid incorporated into a selected gene 
delivery vector. Those teachings are repeated for emphasis 
in the following: 
30 DMEM supplemented with 10% FBS and kept at 37° C. 
with 5% C02 . The MDA-MB-231 and MDA-MB-453 cells 
were maintained in Lebovitz-15 (L-15) medium supple-
mented with 10% FBS and kept at 37° C. without C02 . The 
MDA-MB-435 cells were maintained in L-15 medium 
35 supplemented with 15% FBS and 10 µg/ml bovine insulin 
and kept at 37° C. without C02 . 
Transfection Of Cell Lines With Plasmid DNA And 
Selection Of Stable Transfectants 
Construction of a plasmid containing a full-length human 
1. Immunohistochemistry studies of human prostate can-
cer specimens revealed a down-regulation of prostasin 
in high-grade tumors. 
40 prostasin cDNA under the control of a Rous sarcoma virus 
(RSV) promoter and transfection of cells were carried out as 
described in Chen, L M, Hodge, G B, Guarda, L A et al. 
Down-Regulation of Prostasin Serine Protease, A potential 
Invasion Suppressor in Prostate Cancer, Prostrate 2001, 
48:93-103. Briefly, 1,000,000 MDA-MB-231 or MDA-MB-
435s cells were resuspended in 0.3 ml of the culture medium 
and mixed with 50 µg of plasmid DNA dissolved in 0.1 ml 
of sterile distilled cuvette and pulsed at 200 volts, 1,600 µF, 
72 ohms and 500 V/capacitance setting on a BTX-600 
2. Using RT-PCR and western blot analyses, prostasin 
protein and mRNA expression were found in a non-invasive 45 
human breast cancer cell line, MCF-7, while invasive human 
breast cancer cell lines MDA-MB-231 and MDA-MB-435s 
were found not to express either the prostasin protein or the 
mRNA. A non-invasive human breast cancer cell line, 
MDA-MB-453, was shown to express prostasin mRNA but 
not prostasin protein: and, 
50 Eleciro-cell manipulator (Genetronics, San Diego, Calif.). 
Selection of transfectants was carried out in the presence of 
800 µg/ml G418 (final concentration) until colonies 
appeared. (5-7 days) Colonies (""200 in number) were then 
dispersed via trypsinization and maintained in G418 con-
3. Examination of the prostasin gene promoter in the 
human prostate and breast cancer cell lines by Southern 
blot analysis revealed heterogeneous methylation of the 
promoter in DU-145, PC-3 and MDA-MB453 cells, 
and homogeneous methylation of the promoter in 
MDA-MB-231 and MDA-MB-435s cells. The prosta-
55 taining culture medium without colony-isolation. Cells 
transfected with the human prostasin cDNA construct were 
assayed in Western blot analysis for expression of the 
prostasin protein, using vector-transfected cells as controls. sin gene promoter in normal human prostate epithelial 
cells, the LNCAP and the MCF-7 cells was shown to be 
unmethylated. Transfection of DU-145 and PC-3 cells 
with a full-length human prostasin cDNA restored 
prostasin expression and reduced the in vitro invasive-
ness by 68% and 42%, respectively. Transfection of 
MDA-MB-231 and MDA-MB-435s cells with a full-
length human prostasin cDNA restored prostasin 65 
expression and reduced the in vitro invasiveness by 
50% for either cell line. 
RNA Preparation And Analysis By RT-PCR(Southern 
60 Blot 
Cells grown to 80% confluence (in 60 nm tissue culture 
dish) were lysed directly with 1 ml of the Trizol Reagent 
(life Technologies) and RNA was isolated according to the 
manufacturer's protocol. The human prostasin-specific 
RT-PCR/Southern blot analysis was performed as described 
in Yu, J X, and Chao,J Molecular Cloning, tissue-specific 
expression and cellular localization of human prostasin 
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mRNA. J Biol Chem 1995; 270:12483-4. One microgram of 
total RNA was used in the RT-PCR with 2 human prostasin 
gene-specific oligonucleotide primers, and a Southern blot 
of the resolved RT-PCR samples was probed with a third 
prostasin gene-specific oligonucleotide, detecting an ampli- 5 
fied 232 bp fragment. A co-amplification of the ~-actin 
mRNA for control of RNA quality and quantity was per-
formed as described in Chen Hodge and Guarda, et al. 
20 
Genomic Southern Blot Analysis Of Prostasin Promoter 
Methylation 
High molecular weight genomic DNA was isolated from 
various cell lines as described in Chai, K X, Ward, D C, 
Chao, J, et al Molecular Clonings Sequence Analysis and 
Chromosomal Localization of the Human Protease Inhibitor 
4 (kallistatin) gene (P14) Genomics 1994; 23:370-8. 
Genomic DNA frm each cell line was digested with the 
following restriction enzyme combinations:Xho I/BamH I 
Western Blot Analysis 
Cells grown to 80--100% confluence were washed 3 times 
in lxPBS (pH 7.4) and then lysed in RIPA buffer (lxPBS, 
pH 7.4, 1 % NP-40, 0.5% sodium deoxycholate, 0.1 % SDS). 
The total lysate were centrifuged at 14,000 rpm for 30 
minutes at 4 ° C. to remove the pellet. Protein concentration 
was determined using a DC (detergent-compatible) protein 
assay kit (Bio-Rad, Hercules, Calif.). The samples were then 
subjected to SDS-PAGE followed by Western blot analysis 
using a prostasin-specific antibody. Briefly, cell lysate were 
resolved in 10% gels under reducing conditions before 
electrotransfer to nitrocellulose (NC) membranes (Fisher 
Scientific, Pittsburgh, Pa.). Upon complete protein transfer, 
the NC membranes were blocked in BLOTTO (5% nonfat 
milk made with Tris-buffered saline/0.1 % Tween-20, pH 
7.6), incubated with the prostasin-specific antibody diluted 
at a ratio of 1:2000 in BLOTTO, followed by an incubation 
with the secondary antibody, goat antirabbit IgG conjugated 
10 
(X/B), Xho I/BamH l/Hha (X/B/Hh), Xho I/BamH l/Aci I 
(X/B/A), Xho I/Barn H I.Bsa I (X/B/Bs),Xho I/Barn H l/Msp 
I(X/B/M) or Xho I/Barn H l/Hpa II(X/B/H) using 10 µg of 
DNA per digestion combination. The X/B cutting sites flank 
the CpG sies be to be investigated for differential methyla-
15 tion by the methylation-sensitive restriction endonucleases. 
The digests were resolved in a 0.8% agarose gel and 
analyzed by Southern blot hybridization as described in 
Chai, K X, Ward, D C, Chao, J et al. A nick translated 
prostasin promoter probe (bases 703-1,649) of the prostasin 
20 
gene sequence, Genbank accession number U33446) was 
used for the hybridization. The base numbering of the 
prostasin gene sequence was described in Yu et al. 
Demethylation of Prostasin Gene Promoter and Reactivation 
of Prostasin Expression 
25 
For demethylation of prostasin gene promoter, MDA-
MB-231 and MDA-MB-435s cells were seeded in 100 mm 
to HRP (horseradish peroxidase; used at 1:10,000) (Sigma-
Aldrich, St. Louis Mo.). The bound secondary antibody was 
detected using enhanced chemi-luminesence (ECL) reagents 
30 
(Pierce, Rockford, Ill.) according to the suppliers recom-
mendations. All procedures were performed at room 
temperature, and the membranes were washed between 
steps. 
dishes at an initial density of 50% confluence and cultured 
in the presence of 500 nM 5-aza-2'-deoxycytidine (5-aza-
2'dC; Sigma-Aldrich) for 8 days with renewal of medium 
and 5-aza-2'-dC performed at 2 day intervals. Genomic 
DNA was then isolated for Southern blot analysis as 
described. For reactivation of prostasin expression, MDA-
MB-231 and MDA-MB-435s cells were seeded in 60 mm 
dishes at 80% confluence and cultured in the presence of 500 
Matrigel Chemoinvasion Assay 
The Matrigel chemoinvasion assay was carried out essen-
tially as described in Chen, L. M., Hodge, GB, Guardia, LA 
35 
nM 5-aza-2'-dC for 24 hr, and were then treated for an 
additional 24 hr with either 1 µM trichostatin A(TSA; Sigma 
Aldrich) or an equal volume of 95% ethanol used to dissolve 
TSA. For measuring time-dependence of prostatin gene 
reactivation, cells were treated as described above but were 
et al. Down-Regulation of prostasin serine protease, a poten-
tial invasion suppressor in prostate cancer. Prostate 
2001:48:93-103, incorporated herein. Basement membrane 
Matrigel stock (10 mg/ml; Collaborative Biochemical, 
Bedford, Mass.) was thawed overnight on ice in a refrig-
erator (0-4° C.). Transwell invasion chambers (Coster, 
Cambridge, Mass.) with 8 µm pore polycarbonate filters 
(growth area 0.33 cm2 ) were coated with Matrigel (50 45 
µg/filter, a 1:3 dilution of the stock with chilled serum-free 
medium was used for coating). The gels were solidified by 
incubating the coated filters at 37° C. for 60 min in a moist 
chamber before use. The lower chambers of the Transwell 
plates were filled with 0.6 ml serum-free medium (1-15), 50 
supplemented with 25 µg/ml fibronectin (Sigma-Aldrich). 
Fifty thousand cells in 0.1 ml serum-free OPTI-MEM I 
medium were placed onto each Matrigel-coated filter. The 
filter cartridge was then inserted into the lower chamber and 
the assays were performed at 37° C. for 24 hours (MDA- 55 
MB-435s transfectants) or 72 hour (MDA-MB-231 
transfectants). After removing the medium, the filters were 
washed 3 times in lxPBS, fixed at room temperature for 20 
min in 4% paraformaldehyde made with 0.1 M sodium 
phosphate buffer (pH 7.4) and then washed 3 times with the 60 
sodium phosphate buffer. The filters were then stained with 
1 % toluidine blue (LabChem, Pittsburgh, Pa.) for 2 min. The 
cells on the Matrigel surface were removed with a Q-tip and 
40 
all cells on the underside of the filters were counted under a 
light microscope after mounting the filter on a glass slide. 65 
All invasion assays were done in triplicate for at least 3 
times. 
harvested at 6 or 12 hr after the addition of TSA. RNA was 
isolated for prostasin-specifric RT-PCR/Southern blot analy-
sis as described. The MCF-7 and the MDA-MB-453 cell 
ines were subjected tot the same 5-aza-2'-dC/TSA treatment 
and prostasin RT-PCR Southern blot analysis procedures. 
Results 
Prostasin Expression In Breast Cancer Lines 
Expression of prostasin protein and mRNA in Normal 
Human Mammary Epithelial Cells (NHMEC) and human 
breast carcinoma cell lines was examined by Western blot 
analysis using a prostasin-specific antibody or RT-PCR/ 
Southern blot analysis as described. For this experiment 4 
breast carcinoma cell lines based on their differences in 
invasiveness and metastatic potential were chosen. The 
MCF-7 cell line is poorly invasive to noninvasive, tumori-
genic but nonmetastatic. The MDA-MB-453 cells are poorly 
tumorigenic and nonmetastatic. The MDA-MB-231 and 
MDA-MB-435 cells are both highly invasive and highly 
metastatic. 
As was shown in FIG. 5 (middle panel) a 232 bp amplified 
prostasin message was detected in total RNA of NHMEC, 
MCF-7 and MDA-MB-453 but not MDA-MB-231 or MDA-
MB-435s. A co-amplification of ~-actin message is shown in 
the bottom panel of FIG. 5 to demonstrate the quality and 
quality of total RNA used in each RT-PCR. In addition to the 
expected 232 bp prostasin amplification product, a faint 
bank of retarded mobility was also detected in the Southern 
blot analysis. This retarded band does not represent a new 
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In NHMEC and MCF-7 cells the 1,275 bp Xho I/BamH 
I band can be digested by the methylation-insensitive Msp I 
as well as by the methylation sensitive Hpa II yielding an 
951 bp band, indicating that the CpG at the -96 M/H 
prostasin message, but rather is a single-stranded form of the 
expected prostasin PCR product. In a separate experiment, 
we were able to remove this single-stranded form by treating 
the PCR products with SI nuclease prior to electrophoresis 
(data not shown) 
Re-expression of recombinant human prostasin in invasive 
breast cancer cells reduced in vitro invasiveness 
Following the electroporation and drug selection ""200 
colonies formed for each transfected cell type. All colonies 
for each transfected cell type were kept in a mixed culture 
as polyclonal transfectants for the ensuing experiments. 
Polyclonal MDA-MB-231 and MDA-MB-435s cells trans-
fected with the human prostasin cDNA were confimred to 
express the recombinant human prostasin protein, as shown 
5 restriction site is homogenously unmethylated. In MDA-
MB-453, the 1,275 bp band can be fully digested by Msp I 
but only partially by Hpa II indicating heterogenous methy-
lation of the -96 M/H site CpG. In MDA-MB-231 and 
MDA-MB-435s, the 1,275 bp band was undigested by Hpa 
10 II while having been completely digested by Msp I, indi-
cating that the -96 M/H site CpG is homogenously methy-
lated. 
by Western blot analysis of the cell lysate (FIG. 8, top panel) 
The vector transfected cells were used as negative control in 15 
the Western blot analysis. 
In the in vitro Matrigel chemoinvasion assays shown in 
FIG. 8, bottom panel) transfected MDA-MB-231 or MDA-
MB-345s cells expressing the recombinant human prostasin 
protein showed a significantly reduced level of invasiveness, 20 
at 50% of that of their vector transfected controls, respec-
tively. 
Prostasin Gene Promotor Is Hypermethylated In Invasive 
Breast Cancer Lines 
Overall, in the prostasin-expressing cells the NHMEC is 
the least methylated in this region and the methylation is 
restricted to beyond -266 relative to the transcription ini-
tiation site. The prostasin gene promoter-exon I region in 
MCF-7 and MDA-MB-453 cells is methylated to a higher 
extent than that in the NHMEC. In the MCF-7, methylation 
is restricted to beyond -966, while in the MDA-MB-453, 
methylation is observed at the -96 position and beyond. In 
the cells that do not express prostasin, the promoter-exon I 
region is the most heavily methylated. While in MDA-MB-
231 the methylation is still restricted to the 5'fianking region, 
all CpG sites examined, including 1 of exon 1 ( +24 Aci I site 
CpG) were found to be homogenously methylated in the 
MDA-MB-435s cells. The results showed that the prostasin 
gene promoter-exon 1 region CpG methylation patterns 
correlate with the absence of prostasin expression in the 
human breast cells examined. 
30 Prostasin Expression Was Reactivated By Demethylation 
And Histone Dacetylase Inhibition In The Invasive And 
Metastatic Breast Cancer Cell Lines 
Examination of the prostasin gene locus by genomic 25 
Southern blot-RFLP (restriction fragment length 
polymorphism) analysis did not reveal any evidence of gene 
loss or gross rearrangement in the cell lines that did not show 
prostasin expression, namely, MDA-MB435 (data not 
shown) Consideration of the possibility of prostasin gene-
silencing by epigenetic mechanisms was also considered. 
Polysynthetic methylation of cytosine residues in the 5'-CpG 
islands is often involved in long-term silencing of certain 
genes during mammalian development and in the progres-
sion of cancers. An examination of the prostasin promoter 35 
and exon I region sequence (GenBank accession number 
U33446) identified 28 CpG dinucleotides in a segment 
defined by an Xho I site (vse number 374 of U33446 or 
-1,048 relative to the transcription initiation site and a 
BamH I site (base number 1,649 of U33446 or +228 relative 40 
to the transcription initiation site) (FIG. 9a*) A GC enriched 
domain containing 2 consensus G/C boxes with the 
sequence GGGCGG was identified as encompassing the 
transcription initiation site. This GC enriched domain 
extends from base number 1,101 to the BamH I site (1,649) 45 
as a length of 549 bp and has a GC content of 58.6%. The 
549 bp QC-enriched domain contains 19 CpG dinucleotides, 
but failed to qualify as a true CpG island by the standards of 
Gardiner-Garden, M, and Frommer, M. CpG islands in 
vertebrate genomes. J Mol Biol 1987:196:261-82. 
Methylated promoter DNA may contribute to repression 
of gene expression by interfering with the binding of tran-
scription factors, or by interacting with various methyl-CpG 
binding proteins. Such as the McCP 1 complex, MeCP2 and 
the MBD's depending on cell type, sequence of the methy-
lated regulatory region and binding of other transcription 
factors. Histone deacetylases are recruited by the methyl-
CpG binding proteins to co-repress gene expression via 
chromatin restructuring. Histone deacetylases act synergis-
tically with DNA methylation in the co-repression, with 
DNAmethylation being the dominant force for stable main-
tenance of gene silencing in cancer. Treatment of cancer 
cells with the demethylation agent 5-aza-2'-deoxycytidine 
(5-aza-2'dC) may restore a minimal expression for genes 
silenced by promoter methylation and the combined treat-
ment of 5-aza-2'-dC with the histone deacetylase inhibitor, 
trichostatin A (TSA) may further stimulate the restored 
In all breast cancer cell lines and the NHMEC, Xhol/ 
BamH I/Hha digestion yielded a 1,275 bp prostasin pro-
moter band seen in the Xho I/BamH I/I digestion (**FIG. 9b 
upper panel) indicating that the -807 Hha I site-CpG is 
homogenously methylated. 
50 expression. Investigation of demethylation and/or histone 
deacetylase inhibition could reactive prostasin gene expres-
sion in the MDA-MB-231 and MDAA-MB-435s cells pro-
ceeded as follows: 
After 8 days of treatment with the DNAmethyltransferase 
In the NHMEC digestion with Xho I/Barn H l/Aci I 
yielded a 1,072 bp, a 727 bp and a 345 bp band, but no 1,275 
55 inhibitor 5-aza-2'-dC, a significant level of demethylation 
was observed in the prostasin promoter-exon 1 region in the 
MDA-MB-435s cells, as genomic DNA of this region in 
these cells was partially digested by Hha I at -807, Aci I at bp band, indicating that the -320 Aci I site-CpG is hetero-
geneously methylated but the +24 Aci I site CpG is homog-
enously unmethylated. In MCF-7, MDA-MB-453 and 60 
MDA-MB-231, digestion with Xho I/BamH l/Aci I yielded 
only the 1,072 bp band, indicating that the -320 Aci site 
CpG is homogenously methylated, but the +24 Aci site CpG 
is homogenously unmethylated. In MDA-MB-435s, diges-
tion with Xho l/BamH/Aci I yielded only the 1,275 bp band, 65 
indicating that both the -320 and the +24 Aci I site CpG's 
are homogenously methylated. 
-320, BsaAI at -266 and Hpa Hat -96 (***FIG. 9c). The 
+24 Aci I was also partially digested in MDA-Mb-435s 
following demethylation (FIG. 9c) Examination of total 
RNA of these cells by RT-PCR/Southern blot analysis fol-
lowing the 8-day 5-aza-2'-dC treatment, however, failed to 
detect prostasin mRNA expression (data not shown). 
Investigation of the combined effect of treating the cells 
with 5-aza-2'-dC and TSA, an inhibitor of histone deacety-
lase followed. In RT-PCR/Southern blot analysis, a time-
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dependant reactivated expression of prostasin mRNA was 
observed in both the MDA-MB-231 and the MDA-MB-435s 
cells after a treatment with 5-aza-2'-dC for 24 hr followed by 
95% ethanol (solvent for TSA) did not result in prostasin 
mRNA re-expression. A co-amplification of the ~-actin 5 
message confirmed the quality and quantity of the total RNA 
used in each RT-PCR. When MCF-7 and MDA-MB-453 
cells were subjected to the same 5-aza-2'-dC/TSA treatment 
and prostasin RT-PCR/Southern blot analysis procedures, no 
increase of prostasin mRNA expression was observed for 
either cell line. 10 
FIG. 9a The solid horizontal line represents the promoter-
exon I region of the human promstasin gene (Genbank 
U33446) The Xho I site is located at Base 1,649 of the 
U33446 sequence respectively. The methylation sensitive 
restriction sites used for differential methylation analysis, 15 
Hha (615/-807), Aci I (1,102/-320 and 1,445/+24), BsaA I 
(1,156/-266) and Msp l/Hpa II (1,326/-96) are indicated by 
arrows. Four additional Aci I sites and a second dMsp Ihpa 
Ii site are present between the +24 Aci I site and the Barn H 
I sies but not shown in the figure since they do not affect the 20 
results of the genomic DNA Southern blot analysis. The 
transcription initiation site is indicated by the triangle on an 
extended vertical bar. The vertical bars map the location of 
the 28 CpG dinucleotides identified in this region. A 549 bp 
GC-enriched domain is indicated by the filled rectangular 25 
box. The extended vertical bas with open square boxes 
indicate the locations of the consensus G/Cboxes. The 
location of the probe used in the genomic DNA Southern 
blot analysis is shown by the open rectangular box. 
FIG. 9b. Panels of genomic DNA Southern lot analysis 30 
results are as indicated for each cell type. Restriction endo-
nucleases used in each digestion mixture are indentified as 
follows: X, Xho I, B, Barn H I, Hh, Hha I, A, Aci I, Bs, BsaA 
I, M, Msp I, H, Hpa II. Hha I, Aci I, BsaA I and Hpa II only 
cut unmethylated DNA while Msp I, an isoschizomer of Hpa 35 
Ii, cuts unmethylated or methylated DNA Genomic DNA 
(10 µg) from each cell type was cut with X/B or with XIB/M 
to serve as controls for the detection of differential methy-
lation. In the upper panel, prostasin promoter DNA will 
yield a 1,275 bp X/B fragment. When Hha I was added to the 40 
X/B digestion mixture a fragment of 1,037 bp was expected 
if the -807 Hha I site CpG was not methylated. When Aci 
I was added to the X/B digestion mixture, 3 smaller bands 
might be expected depending on CpG methylation states at 
-320 and +24 Aci I sites. They are 1,072 bp(from Xho I to 45 
+24 Aci I) 727 bp (from Xho I to -320 Aci I) and 345 bp 
(from -320 Aci to +24 Aci I) in length, respectively. When 
BsaA I was added to the X/B digestion mixture, 2 smaller 
bands might be expected depending on CpG methylation 
state at the -266 Bsa A I. They are 782 bp (from Xho I to 50 
BsaA I) and 493 bp (from BsaA I to BamH I) in length, 
respectively (indicated by asterisks in the figure). In the 
lower panel, the upper arrow points to the X/B fragment, 
while the lower arrow points to the fragment that is gener-
ated by Msp I, regardless of DNAmethylation, or by Hpa LI, 55 
only when DNA is unmethylated. 
FIG. 9c Cells treated with 5-aza-2'dC for 8 days were 
harvested for genomic DNA isolation and southern blot 
analysis as described. The arrowhead indicates the 1,037 bp 
Hha I-BamH I fragement when the -807 ha I site was cut by 60 
enzyme following DNA demethylation. 
Example 2 
The same methylated sites investigated in example I 
above in breast cancer cell lines, were investigated in human 65 
prostate cancer cell lines and human prostate epithelial cells. 
All methods were the same, except as follows: 
24 
Cell Culture Maintenance 
A normal human prostate epithelial cell (PrEC) primary 
culture (PrEC primary culture (Catalog Number CC-2555) 
was obtained from Clonetics (San Diego, Calif.) and main-
tained in the supplied medium (prostrate epithelial cell basal 
medium, containing bovine pituitary extract, 
hydrocortisone, human epidermal growth factor, 
epinephrine, transferring, insulin, retinoic acid, tri-
iodothyronine, gentamicin, and amphotericin). The culture 
was kept at 37° C. with 5% C02 and used for experiments 
at the overall passage. 
Human prostate cancer cell lines LNCAP, DU-145 and 
PC-3 were obtained from the American Type Culture Col-
lection (ATCC, Manassas, Va.). The PC-3 cells were main-
tained in F-12K medium supplemented with 10% fetal 
bovine serum (FBS) while the LNCaP and the DU-145 cells 
were maintained in RPMI-1640 medium supplemented with 
10% FBS and 1 mM sodim pyruvate, and all were kept at 
37° C. with 5% C02 . 
Demethylation Of Prostasin Gene Promoter And Reacti-
vation Of Prostasin Expression 
Du-145 and PC-3 cells were seeded in 60-mm dishes at 
80% confluence and cultured in the presence of 500 nM 
5-aza-2'-dC for 24 hours and were then treated for an 
additional 24 hours with either 1 µM trichostatin A (TSA, 
Sigma-Aldrich Co.) or an equal volume of 95% ethanol used 
to dissolve TSA. TNA was isolated for prostasin-specific 
RT-PCR/Southern blot analysis as described in example 1. 
As in example 1, the prostate cells were subjected to 
Southern blot analysis. In all three prostate cancer cell lines 
and the PrEC, XhoI/BamH I/Hha I digestion yielded a 1,275 
bp prostasin promoter band seen in the XhoI/BamH I/Hha I 
digestion (FIG. 10, upper panel), indicating that the -807 
Hha site-CpG is homogeneously methylated. 
In the PrEC, digestion with Xho I/Barn H l/Aci I yielded 
a 1,072 bp, a 727 bp and a 345 bp band, but no 1,275 bp band 
indicating that the -320 Aci I site CpG is heterogeneously 
methylated but the +24 Aci site CpG is homogeneously 
unmethylated. In LNCaP and Du-145, digestion with Xho 
l/BamH l/Aci I ielded only the 1,072 bp band indicating that 
the -320 Aci I site-CpG is homogenously methylated but the 
+24 Aci I site CpG is homogeneously unmethylated. In 
PC-3, digestion with Xho I/BamH l/Aci I yielded the 1,072 
bp band and to a lesser extent the 1,275 band, indicating that 
the -320 Aci I site-CpG is homogensously methylated, 
while the +24 Aci I site pG is heterogeneously methylated. 
In the PrEC and LNCaP digestion with Xho I/BamH 
l/BsaA I yielded a 782 bp and a 493 bp band, indicating that 
the -266 BsaA I site CpG is homogeneously unmethylated. 
In DU-145, digestion with Xho l/BamH I/BasAI yielded the 
782 bp and the 493 bp bands, but also the 1,275 bp band, 
indicating that the -266 BsaAI site-CpG is heterogeneously 
methylated. In PC-3, digestion with Xho/BamH l/BsaA I 
yielded only the 1,275 bp band, indicating that the -266 
BsaA I site-CpG is homogeneously methylated. 
In the PrEC and LNCaP cells, the 1,275 bp Xho I-BamH 
I band can be digested by the methylation-insensitive Msp I 
as well as by the methylation-sensitive Hpa II, yielding a 
951 bp band (FIG. 10, lower panel) indicating that the CpG 
at the -96 M/H restriction site is homogeneously unmethy-
lated. In DU-145 and PC-3, the 1,275 bp band can be fully 
digested by Msp I but only partially by Hpa II (FIG. 10, 
lower panel) indicating heterogeneous methylation of the 
-96 M/H site Cpg. 
The PrEC express both the prostasin mRNA and protein 
and is the least methylated in the prostasin promoter-exon 1 
region (methylation is only observed at beyond -266 rela-
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tive to the transcription initiation site. The prostasin gene 
promoter-exon 1 region in LNCaP cells is methylated to a 
higher extent than that in the PrEC. In LNCaP, which also 
express both the prostasin mRNA and protein, methyltion is 
only observed at beyond -96. In DU-145, which does not 5 
express either the prostasin protein or mRNA, the promoter-
exon 1 region is the most heavily methylated. While in 
DU-145, the methylation is limited to the 5 flanking region, 
all CpG sites examined, including one of exon 1 ( +24 Aci I 
site-CpG) show heterogeneous to homogeneous methylation 
10 
in the PC-3 cells. The prostasin gene promoter-exon region 
prostasin expression in the invasive prostate cancer cells, the 
reactivated expression represents only the basal expression, 
similar to what was observed in the breast cancer cells. 
Examples I and II demonstrate that the methylation pat-
terns of the same specific sites in both breast cancer and 
prostate cancer provide markers for invasiveness. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
of the invention is not intended to be, nor should it be 
deemed to be, limited thereby and such other modifications 
or embodiments as may be suggested by the teachings herein 
are particularly reserved especially as they fall within the 
CpG methylation patterns correlate with the absence of 
prostasin expression in the human prostate cells. 
Table I details the methylation state of the prostate cells. 
breadth and scope of the claims here appended. As shown with the breast cancer cells the methylation state 
of the prostasin promoter region may be examined for a 15 
potential diagnostic application to indicate prostate cancer 
invasiveness. For example, the prostasin gene promoter 
methylation state at the -96M/H CpG site, for example, is 
We claim: 
1. A method for determining whether human prostate or 
breast carcinomas are non invasive, comprising sampling 
human breast or prostate carcinomas and determining 
whether the prostasin gene promoter DNA is methylated at seen methylated in invasive cell types. 
TABLE 1 




Cell Exp res- Hha 1 Aci 1 BsaA 1 
Type sion (-807) (-320) (-266) 
Pr EC Yes Methyl Hetero- Un-Methyl 
methyl 
LNCaP Yes Methyl Methyl Un-Methyl 
DU-145 No Methyl Methyl Hetero-
Methyl 
PC-3 No Methyl Methyl Methyl 
Table Legend: 
Methyl ~ homogeneously methylated 
Hetero-Methyl ~heterogeneously methylated 
Un-Methyl ~ homogeneously unmethylated 
Mspl/ 










In investigating whether methylation in the promoter is 
causal to the lack of prostasin gene expression in the 
DU-145 and PC-3 cells, as in the breast cancer cells, 
treatment of these cell lines for 8 days with the DNA 
methyltransferase inhibitor 5-aza-2'-dC resulted in signifi-
cant level of demethylation but no prostasin mRNA expres-
sion was detected in an RT-PCR/Southern blot analysis of 
the DNA demethylated cells. Treatment of the cells with the 
combination of 5-aza-2'-dC and trichostatin A (TSA) an 
inhibitor or histone deacetylase however restored prostasin 
mRNA expression in DU-145 and PC-3 cells (data not 
shown) When investigating whether the prostasin protein 
was expressed in the 5-aza-2'dC/TSA treated cells by west-
ern blot analyis, the result was negative. It appears that 
although promoter DNAmethylation is causal to absence of 
20 bp 1,156/-266, wherein the absence of methylation indicates 
a non-invasive carcinoma. 
2. The method, as in claim 1 wherein the sampling of the 
carcinoma tissue includes the step of separating the human 
carcinoma tissue from neighboring normal tissue using a 
25 laser capture micro-dissection. 
3. The method, as in claim 1, wherein the step of deter-
mining gene promoter DNA methylation patterns includes 
applying prostasin-promoter-specific oligonucleotide prim-
ers in a PCR to determine the prostasin gene promoter DNA 
30 methylation patterns in the sampled tissue. 
4. A method for determining which cancer patients do not 
require chemotherapeutic treatment, comprising taking a 
biopsy of a prostate or breast tumor, and determining the 
non-invasiveness of the carcinoma tissue based on the 
35 absence of methylation of the prostasin gene promoter DNA 
at bp 1,156/-266. 
5. A method for determining whether human prostate 
carcinomas are non invasive, comprising sampling human 
prostate carcinomas and determining whether the prostasin 
40 gene promoter DNA is methylated at bp 1,156/-266, 
wherein the absence of methylation indicates a non-
invastive caarcinoma and the presence of methylation indi-
cates invasive carcinoma. 
6. The method of claim 5 wherein the sampling of the 
45 carcinoma tissue includes the step of separating the human 
carcinoma tissue from neighboring normal tissue using a 
laser capture micro-dissection. 
7. The method of claim 5, wherein the step of determining 
gene promoter DNA methylation patterns includes applying 
50 prostasin-promoter-specific oligonucleotide primers in a 
PCR to determine the prostasin gene promoter DNAmethy-
lation patterns in the sampled tissue. 
* * * * * 
